ப்யாட்‌ராஸ் பல்கலைக்கழகம் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article FRANKLIN LAKES, N.J., April 29, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV. CONNECT-AV is a prospective, single-arm, open-label study that will follow patients treated with the WavelinQ TM EndoAVF System for 24 months. WavelinQ EndoAVF System The study s dual primary effectiveness endpoints are the percentage of subjects dialyzing using successful 2-needle cannulation for at least 75% of the dialysis sessions over a continuous 28-day period at 6 months, and the subjects maintaining primary patency at 6 months.

United statesButler memorial hospitalPanagiotism kitrouBrandon repkoTroy kirkpatrickKristenm stewartClinical affairsNational institute of diabetesNational institutes of healthClinical events committeePatras university hospitalNuclear imagingMedical directorTherapeutic servicesInterventional radiologyPatras university